Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Epithelial-mesenchymal transition-associated microRNA/mRNA signature is linked to metastasis and prognosis in clear-cell renal cell carcinoma.

Mlcochova H, Machackova T, Rabien A, Radova L, Fabian P, Iliev R, Slaba K, Poprach A, Kilic E, Stanik M, Redova-Lojova M, Svoboda M, Dolezel J, Vyzula R, Jung K, Slaby O.

Sci Rep. 2016 Aug 23;6:31852. doi: 10.1038/srep31852.

2.

Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice.

Poprach A, Lakomy R, Bortlicek Z, Melichar B, Pavlik T, Slaby O, Vyzula R, Svoboda M, Kiss I, Studentova H, Zemanova M, Fiala O, Kubackova K, Dusek L, Hornova J, Buchler T; Czech Renal Cell Cancer Cooperative Group.

Drugs Aging. 2016 Aug 19. [Epub ahead of print]

PMID:
27541802
3.

Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib.

Fiala O, Pesek M, Finek J, Topolcan O, Racek J, Svaton M, Kucera R, Minarik M, Benesova L, Bortlicek Z, Chloupkova R, Poprach A, Buchler T.

Anticancer Res. 2016 May;36(5):2459-65.

PMID:
27127158
4.

Decreased expression levels of PIWIL1, PIWIL2, and PIWIL4 are associated with worse survival in renal cell carcinoma patients.

Iliev R, Stanik M, Fedorko M, Poprach A, Vychytilova-Faltejskova P, Slaba K, Svoboda M, Fabian P, Pacik D, Dolezel J, Slaby O.

Onco Targets Ther. 2016 Jan 8;9:217-22. doi: 10.2147/OTT.S91295. eCollection 2016.

5.

Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.

Buchler T, Bortlicek Z, Poprach A, Pavlik T, Veskrnova V, Honzirkova M, Zemanova M, Fiala O, Kubackova K, Slaby O, Svoboda M, Vyzula R, Dusek L, Melichar B; Czech Renal Cancer Cooperative Group.

Eur Urol. 2016 Sep;70(3):469-75. doi: 10.1016/j.eururo.2015.12.031. Epub 2015 Dec 30.

PMID:
26746623
6.

[A Case of Delayed Dia-gnosis of Acral Lentiginous Melanoma].

Gottvaldová M, Jedličková H, Poprach A, Vašků V.

Klin Onkol. 2015;28(6):439-43. Czech.

PMID:
26673994
7.

[Side effects of Modern Immunotherapy and How to Solve Them in the Clinics].

Lakomý R, Poprach A.

Klin Onkol. 2015;28 Suppl 4:4S103-14. Review. Czech.

PMID:
26647898
8.

Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma.

Krajsová I, Arenberger P, Lakomý R, Kubala E, Březinová I, Poprach A, Šťastný M, Mužík J, Melichar B.

Anticancer Res. 2015 Nov;35(11):6303-10.

PMID:
26504067
9.

High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib.

Fiala O, Pesek M, Finek J, Topolcan O, Racek J, Minarik M, Benesova L, Bortlicek Z, Poprach A, Buchler T.

Tumour Biol. 2015 Dec;36(12):9215-22. doi: 10.1007/s13277-015-3660-3. Epub 2015 Jun 19.

PMID:
26088452
10.

miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.

Merhautova J, Hezova R, Poprach A, Kovarikova A, Radova L, Svoboda M, Vyzula R, Demlova R, Slaby O.

Biomed Res Int. 2015;2015:941980. doi: 10.1155/2015/941980. Epub 2015 May 3.

11.

Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study.

Kubackova K, Melichar B, Bortlicek Z, Pavlik T, Poprach A, Svoboda M, Lakomy R, Vyzula R, Kiss I, Dusek L, Prausova J, Buchler T; Czech Renal Cancer Cooperative Group.

Target Oncol. 2015 Dec;10(4):557-63. doi: 10.1007/s11523-015-0366-9.

PMID:
25903462
12.

Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency.

Poprach A, Bortlicek Z, Melichar B, Lakomy R, Svoboda M, Kiss I, Zemanova M, Fiala O, Kubackova K, Coufal O, Pavlik T, Dusek L, Vyzula R, Buchler T.

Eur J Cancer. 2015 Mar;51(4):507-13. doi: 10.1016/j.ejca.2014.12.010. Epub 2015 Jan 7.

PMID:
25577735
13.

A simple model to assess the probability of invasion in ductal carcinoma in situ of the breast diagnosed by needle biopsy.

Coufal O, Selingerová I, Vrtělová P, Krsička P, Gabrielová L, Fabian P, Stískalová K, Schneiderová M, Poprach A, Justan I.

Biomed Res Int. 2014;2014:480840. doi: 10.1155/2014/480840. Epub 2014 Jul 8.

14.

Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: a registry-based analysis.

Buchler T, Bortlicek Z, Poprach A, Kubackova K, Kiss I, Zemanova M, Fiala O, Dusek L, Vyzula R, Melichar B; Czech Renal Cancer Cooperative Group.

Urol Oncol. 2014 Jul;32(5):569-75. doi: 10.1016/j.urolonc.2013.12.007. Epub 2014 Mar 12.

PMID:
24629497
15.

Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma.

Kiss I, Bortlicek Z, Melichar B, Poprach A, Halamkova J, Vyzula R, Dusek L, Buchler T.

Anticancer Res. 2014 Feb;34(2):949-54.

PMID:
24511038
16.

Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.

Poprach A, Pavlik T, Melichar B, Kubackova K, Bortlicek Z, Svoboda M, Lakomy R, Vyzula R, Kiss I, Dusek L, Buchler T; Czech Renal Cancer Cooperative Group.

Urol Oncol. 2014 May;32(4):488-95. doi: 10.1016/j.urolonc.2013.09.011. Epub 2013 Dec 8.

PMID:
24321257
17.

[Epidemiological and clinico-pathological characteristics of patients with renal carcinoma: a single institution analysis of 544 cases].

Poprach A, Lakomý R, Selingerová I, Dolečková B, Bílek O, Slabý O, Héžová R, Fabian P, Staník M, Pavlík T, Bortlíček Z, Mlčochová H, Tkáč D, Vyzula R, Kiss I, Kocák I, Kocáková I, Svoboda M.

Klin Onkol. 2013;26(2):114-23. Czech.

PMID:
23718670
18.

[Another approach to targeted therapy of patients with metastatic renal carcinoma with progression in treatment with pazopanib:expert assessment by the Czech Cooperative Group for Metastatic Renal Carcinoma].

Büchler T, Finek J, Hájek J, Kocák I, Kubácková K, Lakomý R, Melichar B, Petruzelka L, Poprach A, Siffnerová M, Tomásek J, Vyzula R, Zemanová M; Cezkou Kooperativní Skupinu pro Metastický Renální Karcinom.

Klin Onkol. 2013;26(1):55-7. Czech. No abstract available.

PMID:
23607143
19.

MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma.

Redova M, Poprach A, Besse A, Iliev R, Nekvindova J, Lakomy R, Radova L, Svoboda M, Dolezel J, Vyzula R, Slaby O.

Tumour Biol. 2013 Feb;34(1):481-91. doi: 10.1007/s13277-012-0573-2. Epub 2012 Nov 13.

PMID:
23150176
20.

[The RENIS clinical registry].

Poprach A, Büchler T, Bortlíček Z, Dušek L, Vyzula R.

Klin Onkol. 2012;25(4):299-301. Czech. No abstract available.

PMID:
22920173
Items per page

Supplemental Content

Loading ...
Write to the Help Desk